Publication | Open Access

Development of a Preclinical PK/PD Model to Assess Antitumor Response of a Sequential Aflibercept and Doxorubicin-Dosing Strategy in Acute Myeloid Leukemia

Hematological MalignancyOncologySequential AfliberceptMedicineAcute Myeloid LeukemiaMalignant Blood DisorderImmunologyHematologyPharmacotherapyPharmacologyPreclinical Pk/pd ModelMyeloid Neoplasia